GLP1R and metabolic dysfunction-associated steatotic liver disease: Among currently FDA approved medications (for obesity and/or diabetes treatment), GLP-1 receptor agonists appear especially promising for the treatment of NAFLD (Mahapatra et al., 2022; Patel Chavez et al., 2022).